Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Cash & Current Investments (2009 - 2025)

Grifols' (GRFS) quarterly Cash & Current Investments came in at $51.2 million in Q4 2025, down 96.07% YoY from $1.3 billion in Q4 2024, and down 96.07% on a QoQ basis from $1.3 billion in Q4 2024.

Grifols (GRFS) Cash & Current Investments (2009 - 2025) Analysis & Trends

Grifols (GRFS) has 17 years of Cash & Current Investments data on file, last reported at $51.2 million in Q4 2025.

  • Quarterly Cash & Current Investments fell 96.07% year-over-year to $51.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $51.2 million (down 96.07% YoY) and the FY2025 annual result came in at $51.2 million, down 96.07% from the prior year.
  • Cash & Current Investments declined to $51.2 million in Q4 2025, from $1.3 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $3.1 billion in Q4 2021 to a low of $51.2 million in Q4 2025.
  • A 5-year average of $1.1 billion and a median of $604.7 million in 2022 frame the typical range for Cash & Current Investments.
  • Annual changes were most pronounced in 2021 — Cash & Current Investments surged 335.16% — and 2025, when it plunged 96.07%.
  • Tracing GRFS's Cash & Current Investments over 5 years: stood at $3.1 billion in 2021, then sank by 80.27% to $604.7 million in 2022, then decreased by 1.66% to $594.6 million in 2023, then soared by 119.07% to $1.3 billion in 2024, then sank by 96.07% to $51.2 million in 2025.
  • The last three Cash & Current Investments figures came in at $51.2 million (Q4 2025), $1.3 billion (Q4 2024), and $594.6 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 20.76 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 6.57 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 7.14 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 7.69 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 4.90 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 13.99 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 3.18 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 11.70 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 4.17 Bn
10 Grifols 5.45 Bn 4.45 Bn - 1.00 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 51.22 Mn
Dec 31, 2024 1.30 Bn
Dec 31, 2023 594.61 Mn
Dec 31, 2022 604.66 Mn
Dec 31, 2021 3.07 Bn
Dec 31, 2020 704.36 Mn
Sep 30, 2020 1.22 Bn
Mar 31, 2020 718.37 Mn
Dec 31, 2019 210.85 Mn
Sep 30, 2019 884.51 Mn
Mar 31, 2019 858.09 Mn
Dec 31, 2018 1.24 Bn
Sep 30, 2018 736.73 Mn
Jun 30, 2018 320.61 Mn
Mar 31, 2018 1.05 Bn
Dec 31, 2017 1.06 Bn
Jun 30, 2017 2.98 Bn
Dec 31, 2016 969.15 Mn
Sep 30, 2016 561.51 Mn
Jun 30, 2016 1.28 Bn